Cepton Unveils Vista®-X90, Sets New Standard for High Performance, Automotive-Grade Lidar
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced details of its groundbreaking automotive-grade lidar sensor – the Vista®-X90, priced at less than $1000 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005088/en/
With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, the compact, non-rotational Vista-X90 allows seamless vehicle integration. © 2020 Cepton Technologies.
The Vista-X90 is the newest addition to Cepton’s Vista-X automotive grade sensor family. It sets a new benchmark for high performance at low power in a compact form factor, and is ideally suited for advanced driver assistance systems (ADAS) and autonomous vehicles (AVs). Weighing less than 900 g, the Vista-X90 achieves up to 200 m range at 10% reflectivity with an outstanding angular resolution of 0.13° and state-of-the-art power consumption of <12W. The sensor supports frame rates of up to 40 Hz.
Optimized for ease of vehicle integration, the Vista-X90 has a licensable design architecture powered by Cepton’s patented Micro Motion Technology (MMT®) – a frictionless, mirrorless, rotation-free lidar architecture capable of high resolution and long range 3D imaging, while maximizing the sensor robustness and reliability to meet the stringent requirements of automotive applications.
Powered by Cepton’s next generation ASIC technology, the Vista-X90 is an ISO26262 ASIL-B sensor that supports AUTOSAR and over-the-air (OTA) functionality, with advanced capabilities for factory, extrinsic and dynamic calibration. With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, Vista-X90 is compact and embeddable. Its 90° x 25° field of view, combined with its directional, non-rotational design allows seamless vehicle integration - such as in the fascia, behind the windshield or on the roof.
Built with easily available and inexpensive components using a highly manufacturable, modular and scalable architecture, the Vista-X90 is ideally suited for high volume production to bring truly cost-effective lidar solutions to ADAS and AV markets. Cepton has licensed its technology to the world’s largest automotive headlamp Tier 1, Koito, who has non-exclusive rights to manufacture and sell Cepton’s lidar technology for an automotive application, using key modules supplied by Cepton.
“We are excited to disrupt the industry with the Vista-X90, which is the most cost-effective, high-performance lidar in the world for automotive applications,” said Dr. Jun Pei, Cepton’s CEO. “Automotive lidars have historically had either low performance at acceptable cost or claimed high performance while being too expensive for many OEM programs. The Vista-X90 fundamentally changes the game by bridging that divide and delivering the optimal mix of performance, power, reliability and cost. This is an integral part of our plan to make lidar available as an essential safety device in every consumer vehicle in the world.”
The Vista-X90 is targeted for production in 2022 and beyond, and samples can be made available upon request.
To learn more about the Vista-X90 and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming Automotive Lidar 2020 conference next week, between September 22 – 24, 2020. Please visit our virtual booth page and sign up to hear Cepton’s Senior Director of Business Development, Mitch Hourtienne, discuss the Vista lidars in his talk “Importance of Tier 1 Collaboration for an Automotive ADAS Production Program” on September 23 at 11:15 am EST.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as autonomous driving, ADAS, intelligent transportation systems (ITS), smart spaces and industrial robotics. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, UK, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005088/en/
Contact information
Faithy Li, Cepton Technologies, media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom